Le récepteur de type 3 des FGF (FGFR3) : De la chondrodysplasie… au cancer de la vessie

Medecine/Sciences

Volumn 17, Issue 11, 2001, Pages 1189-1191

  Radvanyi, François ^a   Thiéry, Jean Paul ^a   Billerey, Claude ^b   van der Kwast, Theo H ^c   Zafrani, Élie Serge ^d   Chopin, Dominique ^e  

^a INSTITUT CURIE   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^d HENRI MONDOR HOSPITAL   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996142271     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/200117111189     Document Type: Article

References (16)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-25.
2. Bonaventure J, Rousseau F, Legeai-Mallet L, et al. Récepteurs des facteurs de croissance fibro-blastique (FGFR) et anomalies héréditaires de l’ossification enchondrale et membranaire. Med Sci 1996; 12: 44-9.
3. Webster MK, Donoghue DJ. FGFR activation in skeletal disorders : too much of a good thing. Trends Genet 1997 ; 13: 178-82.
4. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4 ;14) (p16.3 ;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997 ; 16: 260-4
5. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997 ; 90 : 4062-70.
6. Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92: 2987-9.
7. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025-34.
8. Stec I, Wright TJ, van Ommen GJ, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998; 7: 1071-82.
9. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 ; 23: 18-20.
10. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001 ; 158: 1955-9.
11. Karoui M, Hofmann-Radvanyi H, Zimmerman n U, et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001; 20: 5059-61.
12. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27: 1-13, vii.
13. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994 ; 54 : 784-8.
14. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001 ; 61 : 1265-8.
15. Sybley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20: 686-91.
16. Ronchetti D, Greco A, Compasso S, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14) : comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001; 20: 3553-62.